Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults

Pediatr Hematol Oncol. 2022 May;39(4):370-378. doi: 10.1080/08880018.2021.1988012. Epub 2021 Oct 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Administration, Intravenous
  • Child
  • Humans
  • Interleukin 1 Receptor Antagonist Protein* / adverse effects
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Receptors, Antigen, T-Cell
  • Young Adult

Substances

  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Antigen, T-Cell
  • tisagenlecleucel